Xeris Biopharma Holdings (XERS) Other financing activities (2020 - 2023)

Xeris Biopharma Holdings has reported Other financing activities for 4 years, with the latest figure at $1.2 million in Q4 2023.

• For the quarter ending Q4 2023, Other financing activities rose 1875.0% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2023 stood at $1.2 million (down 75.7% YoY), and the FY2023 full-year result was $1.2 million, down 75.7% from the prior year.
• Other financing activities for Q4 2023 stood at $1.2 million, up from $60000.0 in the prior quarter.
• The five-year high for Other financing activities was $3.6 million in Q1 2022, with the low at -$1.2 million in Q4 2020.
• Historically, Other financing activities has averaged $603750.0 across 4 years, with a median of $109500.0 in 2022.
• Annual changes were most pronounced in 2022 — Other financing activities soared 394.44% — and 2023, when it surged 1875.0%.
• Xeris Biopharma Holdings' Other financing activities stood at -$1.2 million in 2020, then surged by 95.61% to -$54000.0 in 2021, then soared by 211.11% to $60000.0 in 2022, then surged by 1875.0% to $1.2 million in 2023.
• The last three Other financing activities figures came in at $1.2 million (Q4 2023), $60000.0 (Q4 2022), and $159000.0 (Q3 2022), per Business Quant data.